about
sameAs
Weight gain is associated with medial contact site of subthalamic stimulation in Parkinson's diseaseAutomated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorderHypernasality associated with basal ganglia dysfunction: evidence from Parkinson's disease and Huntington's diseaseAutomatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia DysfunctionObjective acoustic quantification of phonatory dysfunction in Huntington's diseaseA loud auditory stimulus overcomes voluntary movement limitation in cervical dystonia."Silly walks" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias.Czech version of Rey Auditory Verbal Learning test: normative data.Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson's disease and normative data.Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease.Physiotherapy in Parkinson's Disease: Building ParkinsonNet in CzechiaEye movements in ephedrone-induced parkinsonismAbnormal activity in the precuneus during time perception in Parkinson's disease: an fMRI study.Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's diseaseThe subthalamic microlesion story in Parkinson's disease: electrode insertion-related motor improvement with relative cortico-subcortical hypoactivation in fMRIMotor matters: tackling heterogeneity of Parkinson's disease in functional MRI studiesBasal ganglia neuronal activity during scanning eye movements in Parkinson's diseaseSpatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).Distinct populations of neurons respond to emotional valence and arousal in the human subthalamic nucleusPredicting Falls in Parkinson Disease: What Is the Value of Instrumented Testing in OFF Medication State?Resting-state functional magnetic resonance imaging of the subthalamic microlesion and stimulation effects in Parkinson's disease: Indications of a principal role of the brainstemDisease-Specific Regions Outperform Whole-Brain Approaches in Identifying Progressive Supranuclear Palsy: A Multicentric MRI Study.Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.Event-related potentials in Parkinson's disease: a review.Quantitative assessment of motor speech abnormalities in idiopathic rapid eye movement sleep behaviour disorder.Comparative analysis of speech impairment and upper limb motor dysfunction in Parkinson's disease.Motion and emotion: anxiety-axial connections in Parkinson's disease.Rare alleles within the CYP2E1 (MEOS system) could be associated with better short-term health outcome after acute methanol poisoning.Long-term visual damage after acute methanol poisonings: Longitudinal cross-sectional study in 50 patients.Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases.The Prague Stroop Test: Normative standards in older Czech adults and discriminative validity for mild cognitive impairment in Parkinson's disease.Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.Separate neural representations of depression, anxiety and apathy in Parkinson's disease.Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.Sleep disturbances in untreated Parkinson's disease.Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.Fast vergence eye movements are disrupted in Parkinson's disease: A video-oculography study.Characteristics and occurrence of speech impairment in Huntington's disease: possible influence of antipsychotic medication.Atrophy of caudate nucleus in Huntington's disease measured by computed tomography.
P50
Q28729091-D39F7DCA-776C-4838-8B5E-C415BD7F2AE5Q30356478-F99C54A7-3601-4DE0-9420-0147D6662CABQ30372951-638594E7-D3A4-4EDB-A6BC-39E4E0CDDBE3Q30405128-CA0A0C78-8C28-4F22-ABB7-44F48900AF65Q30453596-3D6FA12C-0BAC-478D-9041-36649D41D8F4Q30462341-F535C3AD-8FEA-4EEF-BB5E-E2F604250768Q30502662-6C7C84D8-0220-4549-A943-ED7DC0F28ADBQ30717161-D59DEDD9-A314-4357-A328-4D198CC7DC5AQ30912738-D18B3BFF-2986-4AAB-89EE-FB359EDB3279Q31802953-10216001-A707-4D84-949F-1569BAAB3646Q33762389-C55265E7-907B-43DB-AA9E-927C5DBC08E5Q34035394-93FA8654-D968-4E4B-BC98-2F864A7FB575Q34125162-AF68AA21-E74A-4297-B5BD-7CED26851920Q34215600-E0D060A6-E8BC-49A0-A1C3-BCF362DD6510Q34473955-2D41888F-66AE-4391-AEE8-A351AA210FC6Q34589859-97C567AA-0923-4E6F-86B5-D4E129A977FEQ35040203-B97C222C-B927-4ECB-A536-58BD20C5728EQ35102755-38362B5D-1C55-446C-9B17-AE04A2C2404FQ35189966-F48302B9-2A8A-47E3-9B96-96053F287420Q35800721-E4EE8AB7-B6DA-43BD-964C-1A04FB5E3AC6Q36076931-026DBC12-A13F-4AAB-95B2-A65ABC80F726Q37683134-C59CA1DB-5E51-402E-9369-9ECF7BE95331Q38122127-64538661-7BA5-40B2-BD4B-EFA295636654Q38184392-247F3844-7E6B-466D-9A8C-FE189AFFC2F0Q38954289-35E68DA2-BF01-4951-B54D-81F656599D0BQ39117135-62CE034A-E7DF-437E-AD25-68B7085DEE89Q39160382-518BA9A3-F46D-4EE4-82B2-29FF3AF111DCQ40216821-B417D439-DE1F-4738-A1C6-65C77B06287EQ40312820-A4459353-2A1F-4FB6-80EA-295C5BECB3D3Q40371880-135E253C-D554-4DD1-9C05-AFC8274425AAQ40600775-F697BDFC-E97E-4BAA-A27C-E505D9A98C6DQ41433471-ED9FBB19-F08C-4590-A75C-042E2F654282Q41954797-6E5E0B82-EAFF-4686-B525-B24EA4229C40Q42957249-00D32804-0D2C-4E23-A4FB-CEF0B20C3A05Q43679755-5ED4ACAF-4DAE-42D6-B28B-1D7358173627Q44499646-4EF85D8A-97DA-4075-902F-31E82EE0AB9BQ44979109-F0A64AD9-5347-4B64-B261-D257C5CA6E58Q45160258-ACA65684-8450-49D6-9B30-0E00F6AB69AEQ45299193-327A691A-58F4-4667-B1AC-9F3D5FD2F6FFQ45302071-EAD28DFA-79C8-4133-A5A8-F4B093474528
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Evžen Růžička
@ast
Evžen Růžička
@en
Evžen Růžička
@es
Evžen Růžička
@nl
Evžen Růžička
@sl
type
label
Evžen Růžička
@ast
Evžen Růžička
@en
Evžen Růžička
@es
Evžen Růžička
@nl
Evžen Růžička
@sl
prefLabel
Evžen Růžička
@ast
Evžen Růžička
@en
Evžen Růžička
@es
Evžen Růžička
@nl
Evžen Růžička
@sl
P106
P21
P31
P496
0000-0002-4893-9661
P569
2000-01-01T00:00:00Z